Lantern Pharma (LTRN) received a USPTO Notice of Allowance for a U.S. patent on LP‑284 treatment methods for mantle cell lymphoma (MCL), double‑hit lymphoma (DHL), and other blood cancers, with expected protection into 2042 once issued.The allowed claims cover LP‑284 as a monotherapy and in combination with specified anti‑cancer agents, and include intravenous and intraperitoneal administration routes. This method‑of‑treatment patent will layer on top of existing LP‑284 composition‑of‑matter patents that protect the drug into 2039 across major markets including the United States, European Union, Japan, China, India, Mexico, Korea, and Australia. LP‑284 holds three FDA Orphan Drug Designations and is in an ongoing Phase 1a trial (NCT06132503) in relapsed or refractory B‑cell non‑Hodgkin's lymphomas and solid tumors, supported by preclinical potency data and an estimated $4 billion annual global blood cancer market opportunity.

Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

Abstract. CD19-directed chimeric antigen receptor (CAR)-T cells are breakthrough therapies for large B-cell lymphomas, but fewer than half of patients achieve durable responses. We previously showed R...

To describe a multidisciplinary workflow for diagnosing and managing unilateral orbital lymphoma, illustrated through cases from a tertiary referral practice.

The European Research Council (ERC) has awarded a Starting Grant to Professor Dr. Dr.

Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent...

Analysis of longitudinal blood samples shows that CD19 CAR T cells can be detected at least 10 years after treatment in patients with lymphoma, with deeper profiling from a single patient showing that...

No description available

B-cell lymphomas can resist macrophage-mediated phagocytosis through different mechanisms. Here the authors present the results of a high-throughput system to screen for antibodies enhancing macrophag...

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

PeproMene Bio has released groundbreaking findings in The Lancet showcasing the potential of PMB-CT01, a novel CAR-T cell therapy, for treating resistant B-cell lymphomas in patients.

PeproMene Bio announces exciting results from a Phase 1 clinical trial, highlighting durable responses in treating relapsed B-cell lymphomas. Featured in The Lancet.

PeproMene Bio recently published significant results in The Lancet, revealing their innovative CAR T-cell therapy's efficacy for treating B-cell lymphomas, even after prior treatment failures.

PeproMene Bio has published groundbreaking Phase 1 trial results in The Lancet, showcasing durable responses in tough B-cell lymphoma cases.

PeproMene Bio has announced the publication of significant Phase 1 trial results in The Lancet demonstrating effective CAR T-cell therapy for B-cell lymphomas.

Lymphomas account for approximately 5% of human malignancies and are classified as Hodgkin or non-Hodgkin variants. Non-Hodgkin lymphomas (NHL) constitute nearly 90% of all lymphomas, with diffuse…

Read the full paper: Genome-wide CRISPR screens identify an RXR–MYLIP–LDLR axis regulating BH3 mimetic sensitivity in peripheral T-cell lymphomas